Zacks Investment Research
16 Jul 2026, 22:52 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Viking Therapeutics (VKTX) currently holds a Zacks Rank of #4 (Sell). — A 'Sell' rating from a quantitative model often triggers immediate downward pressure or reduced appetite from institutional and retail traders.
-0.60Viking Therapeutics' upcoming EPS is projected at -$1.21, representing a 108.62% drop compared to the same quarter last year. — A significant projected increase in losses suggests deteriorating near-term financial performance, which is typically viewed negatively.
-0.50VKTX shares appreciated by 24.83% over the past month, significantly outperforming the Medical sector and the S&P 500. — Strong recent momentum indicates high investor interest and positive sentiment despite the current 'Sell' rank.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company's stock declined in the recent session, is assigned a Zacks Rank of #4 (Sell), and has a projected EPS drop of 108.62%.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1h ago
